Causes and problems of nonresponse or poor response to drugs

Drugs

Volumn 51, Issue 4, 1996, Pages 552-570

  Lacombe, Pau Salvà ^a   Vicente, Juan Antonio García ^a   Pagès, Joan Costa ^a   Morselli, Paolo Lucio ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NITRATE; PHENYTOIN;

ANTIBIOTIC RESISTANCE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESISTANCE; DRUG RESPONSE; DRUG TOLERANCE; HUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOKINETICS; RACE DIFFERENCE; RECEPTOR DOWN REGULATION; REVIEW; TACHYPHYLAXIS; TREATMENT FAILURE;

EID: 0029929703     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651040-00004     Document Type: Review

References (162)

1. Abrams J. The mystery of nitrate resistance. Am J Cardiol 1991; 68: 1393-6
2. Elkayam U. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance and strategies for prevention. Ann Int Med 1991; 114: 667-77
3. Cramer JA, Spilker B, editors. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991
4. Guscott R, Grof P. The clinical meaning of refractory depression: a review for the clinician. Am J Psychiatry 1991; 148: 695-704
5. Kruse W. Patient compliance with drug treatment: new perspectives on an old problem. Clin Invest 1992; 70: 163-6
6. Task Force for Compliance. Non compliance with medications: an economic tragedy with important implications for health care reform. Baltimore (MD): Task Force for Compliance, 1993 Nov
7. International Medical Benefit/Risk Foundation. Improving patient information and education on medicines. Geneva: IM-BRF, 1993 Oct
8. Hall FC. Prediction of response to therapy and mechanisms of resistance. Semin Oncol 1977; 4: 193-202
9. Pratt WB. Drug resistance. In: Pratt WB, Taylor P, editors. Principles of drug action: the basis of pharmacology. 3rd ed. London: Churchill-Livingstone, 1990: 565-638
10. Borst P. Genetic mechanisms of drug resistance: a review. Acta Oncol 1991; 30: 87-105
11. Vendrik CPJ, Bergers JJ, De Jong WH, et al. Resistance to cytostatic drugs at the cellular level. Cancer Chemother Pharmacol 1992; 29: 413-29
12. Overstreet DH, Yamamura NI. Receptor alterations and drug tolerance. Life Sci 1979; 25: 1865-78
13. Lefkowitz RJ, Caron MG, Stiles GL. Mechanisms of membrane receptor regulation: biochemical, physiological and clinical insights derived from studies of the adrenergic receptors. N Engl J Med 1984; 310: 1570-9
14. Cros G. Mécanismes de la désensibilization des recepteurs béta-adrenergiques. Bull Eur Physiopathol Respir 1985; 21: 35-43
15. Katz RJ. Mechanisms of nitrate tolerance: a review. Cardiovasc Drugs Ther 1990; 4: 247-52
16. Bourne HR, Roberts JM. Drug receptors and pharmacodynamics. In: Katzung BG, editor. Basic and clinical pharmacology. 5th ed. New Jersey: Prentice-Hall International, 1992: 10-34
17. Netter KJ. Mechanisms of mono-oxygenases induction and inhibition Pharmacol Ther 1987; 33: 1-9
18. Perucca E, Richens A. Biotransformations. In: Levy R, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1989: 31-50
19. Bock KW, Lilienblum W, Fischer G, et al. Induction and inhibition of conjugating enzymes with emphasis on UDP-glucuronyltransferases. Pharmacol Ther 1987; 33: 23-7
20. Okey AB. Enzyme induction in the cytochrome P450 system. Pharmacol Ther 1989; 45: 241-98
21. Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 1987; 33: 139-44
22. Hittle JB, Crabb DW. The molecular biology of alcohol dehydrogenase: implications for the control of alcohol metabolism. J Lab Clin Med 1988; 122: 7-15
23. Morselli PL, Rizzo M, Garattini S. Interactions between phenobarbital and diphenylhydantoin in animals and in epileptic patients. Ann NY Acad Sci 1971; 179: 88-107
24. McInnes GT, Brodie MJ. Drug interactions that matter: a critical reappraisal. Drugs 1988; 36: 83-110
25. Morselli PL. Role of drug metabolism in drug disposition and effects. In: Pacifici GM, Fracchia GN, editors. Advances in drug metabolism. EUR 15439-EN. Bruxelles, Luxembourg: European Commission, 1995: 3-33
26. Rizack MA, Hilman CDM. Handbook of adverse drug interactions. New York: Med Lett. 1987
27. Patat A. Interactions médicamenteuses: problèmes méthodologiques. Therapie 1995; 50: 203-14
28. Pauwels R. Récepteurs adrenergiques bronchiques et asthme: la tachyphylaxie et sa prevention. Allerg Immunol (Paris) 1988; 20: 261-5
29. Lefkowitz RJ, Stadel JM, Caron MG. Adenylate cyclase coupled beta-adrenergic receptors: structure and mechanisms of activation and desensitization. Annu Rev Biochem 1983; 52: 159-86
30. Pazos A. Acciones de los fármacos: interacciones fármacos y receptor. In: Florez J, Armijo JA, Mediavilla A, editors. Farmacología humana. 2nd ed. Barcelona: Salvat, 1992: 7-17
31. Bassenge E, Grewe R. Bases pharmacologiques de l'échappement thérapeutique. Presse Med 1988; 17: 985-91
32. Brunizeel PLB, Meurs H, Leferink JG, et al. Some fundamental points concerning the clinical aspects of desensitization. Bull Eur Physiopathol Respir 1985; 21: 45s-52s
33. Garreau M, De Wilde J, Frattola L, et al. Anxiolytics and dependence: two double-blind studies of alpidem versus benzodiazepines. In: Racagni G, Brunello N, Fukuda T, editors. Biological psychiatry. Vol. 1. Amsterdam: Excerpta Medica, 1991: 696-8
34. Lorenzo P, Leza JC, Lisazoan I. Drogodependencias. In: Velasco A, Lorenzo P, Serrano JS, et al., editors. Velázquez farmacología. 16th ed. Madrid: Interamericana-McGraw-Hill, 1993: 499-529
35. Morselli PL. Anxiolytic therapy in the elderly. In: Bartholini G, Garreau M, Zivkovic B, editors. Imidazopyridines in anxiety disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1993: 215-22
36. Frattola L, Garreau M, Piolti R, et al. Comparison of the efficacy, safety and withdrawal of alpidem and alprazolam in anxious patients. Br J Psychiatry 1994; 164: 94-100
37. Weber RW, Smith JA, Nelson HS. Aerosolized terbutaline in asthmatics: development of subsensitivity with long-term administration. J Allergy Clin Immunol 1983; 27: 417-22
38. Aarli JA. Effect of clonazepam (Ro-4023) on epileptic seizures. Acta Neurol Scand 1973; 49: 11-7
39. Sato S. Benzodiazepine: clonazepam. In: Levy R, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1989: 725-34
40. Nierenberg AA, Amsterdam JD. Treatment resistant depression: definition and treatment approaches. J Clin Psychiatry 1990; 51 Suppl. 6: 39-47
41. Monti JM, Attali P, Monti DB, et al. Zolpidem and rebound insomnia: a double blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 1994; 27: 166-75
42. Venter JC. High efficacy coupling between beta-adrenergic receptors and cardiac contractility: direct evidence for beta-adrenergic 'spare' receptors. Mol Pharmacol 1979; 16: 429-40
43. Parker JO, Farrel LB, Lahey KA, et al. Effect of interval between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med 1987; 316: 1440-4
44. Thadani U, Whitsett J, Hamilton ST. Nitrate therapy for myocardial ischemic syndrome: current perspective including tolerance. Curr Probl Cardiol 1988; 13: 723-84
45. Flaherty JT. Nitrate tolerance: a review of the evidence. Drugs 1989; 37: 523-50
46. Stewart DD. Remarkable tolerance to nitroglycerin. Philadelphia: Polyclinic, 1988: 172
47. Laws GC. The effect of nitroglycerin upon those who manufacture it. JAMA 1989; 31: 793
48. Danahy DT, Aronow WS. Haemodynamic and antianginal effect of high dose oral isosorbide dinitrate after chronic use. Circulation 1977; 56: 205-12
49. Thadani U, Fung HL, Darke AC, et al. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose response during acute and sustained therapy. Am J Cardiol 1982; 49: 411-9
50. Frishman WH, Giles T, Greenberg S, et al. Sustained high dose nitroglycerin transcutaneous patch therapy in angina pectoris: evidences for attenuation of the effect over time. J Clin Pharmacol 1989; 29: 1097-105
51. James MA, Papouchado M, Jones JV. Attenuation of nitrate effect during an intermittent treatment regimen and the time course of nitrate tolerance. Eur Heart J 1991; 12: 1266-72
52. Colucci WS, Williams GH, Alexander RW, et al. Mechanism and implication of vasodilator tolerance in the treatment of congestive heart failure. Am J Med 1991; 71: 89-99
53. Elkayam U, Kulick D, McIntosh N, et al. Incidence of early tolerance to haemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation 1987; 75: 577-84
54. Packer M, Lee WH, Kessler PD, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987; 317: 799-809
55. Parker JO, Fung HL. Transdermal nitroglycerin in angina pectons. Am J Cardiol 1984; 54: 471-6
56. Ignarro LJ, Lippton H, Edwards JC, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrates, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediate. J Pharmacol Exp Ther 1981; 218: 739-49
57. Murad F, Waldman SA, Fiscus RR, et al. Regulation of cyclic GMP synthesis and the interaction with calcium. J Cardiovasc Pharmacol 1988; 8 Suppl. 8: S57-60
58. Moncada S, Radomsky MV, Palmer RM. Endothelium-derived relaxing factor: identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol 1988; 37: 2495-501
59. Needleman P, Jakshik B, Johnson EM. Sulphydryl requirement for relaxation of vascular smooth muscle. J Pharmacol Exp Ther 1973; 187: 324-31
60. Fung H. Pharmacokinetics and pharmacodynamics of organic nitrates. Am J Cardiol 1987; 60: 4H-9H
61. Torresi J, Horowitz JD, Dusting GI. Prevention and reversal of tolerance to nitroglycerin with N-acetylcysteine. J Cardiovasc Pharmacol 1985; 7: 777-83
62. Munzel T, Holtz J, Mulsch A, et al. Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist. Circulation 1989; 79: 188-97
63. Dupuis J, Lalonde G, Lemiux R, et al. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990; 16: 932-4
64. Luke R, Sharpe N, Coxon R. Transdermal nitroglycerin in angina pectoris: efficacy of intermittent application. J Am Coll Cardiol 1987; 10: 642-6
65. Sharpe N, Coxon R, Webster M, et al. Haemodynamic effects of intermittent transdermal nitroglycerin in chronic congestive heart failure. Am J Cardiol 1987; 59: 895-9
66. Amsterdam EA. Rationale for intermittent nitrate therapy. Am J Cardiol 1992; 70: 44-59
67. Pallarés R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474-80
68. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333: 481-6
69. Hogerzeil HV. Promoting rational prescribing: an international perspective. Br J Clin Pharmacol 1995; 36: 1-6
70. Woodhouse JR, Ferry DR. The genetic basis of resistance to cancer chemotherapy. Ann Med 1995; 27: 157-67
71. Veterans Administration Cooperative Study Group on Anti-Hypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension JAMA 1982; 248: 1966-2003
72. 1 adrenoceptor blockade by propranolol. J Cardiovasc Pharmacol 1984; 6: 36-4
73. Rutledge DR, Steinberg JS, Cardozo L. Racial differences in drug response: isoproterenol effects on heart rate following intravenous metoprolol. Clin Pharmacol Ther 1989; 45: 380-6
74. Johnson JA, Burlew BS. Racial differences in propranolol pharmacokinetics. Clin Pharmacol Ther 1992; 51: 495-500
75. Edeki TI, Brase DA. Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors. Drug Metab Rev 1995; 27: 449-69
76. Grant LF, Brosen K. Conditions under which genetic polymorphisms are clinically relevant. In: Alvan G, Balant LP, Bechtel PR, et al., editors. European Consensus Conference on Pharmacogenetics. ECSC-EEC-EAEC-EUR 12379. Bruxelles, Luxembourg: 1990; 87-96
77. Bertilsson L, Dahl ML, Ingelman-Sundberg M, et al. Interindividual and interethnic differences in polymorphic drug oxidation: implications for drug therapy with focus on psychoactive drugs. In: Pacifici GM, Fracchia GN, editors. Advances in drug metabolism. EUR 15439-EN. Bruxelles, Luxembourg: European Commission, 1995; 85-136
78. Kalow W, Grant DM. Genetic variations of drug metabolizing enzymes. In: Pacifici GM, Fracchia GN, editors. Advances in drug metabolism. EUR 15439-EN. Bruxelles, Luxembourg: European Commission, 1995; 57-84
79. Alós, I. Resistencia bacteriana a los antibióticos: the never ending story. Med Clin (Barc) 1994; 103: 94-6
80. López-Yeste ML, Chaves J, Garau JM, et al. Pérdida de sensibilidad a los antibióticos de cepas de Pseudomonas aeruginosa en el curso del tratamiento. Med Clin (Barc) 1994; 103: 81-4
81. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994; 264: 375-82
82. Schimke RT, Kaufman RJ, Alt FW, et al. Gene amplification and drug resistance in cultured murine cells. Science 1978; 202: 1051-5
83. Carman MD, Schornagel JH, Rivest RS, et al. Resistance to methotrexate due to gene amplification in a patient with acute leukemia. J Clin Oncol 1984; 2: 16-20
84. Horns RC, Dower WJ, Schimke RT. Gene amplification in a leukaemic patient treated with methotrexate. J Clin Oncol 1984; 2: 2-7
85. Barg N. Antibiotic therapy in 1994: mechanisms of resistance. Hosp Formul 1994; 29: S13-7
86. Hanschumacher RE, Calabresi P, Webb AD, et al. Summary of current information on 6-azauridine. Cancer Chemother Res 1962; 21: 1-18
87. Field RB, Gang M, Kline I, et al. The effect of phenobarbital or 2-diethylaminoethyl 2-1-2-diphenyl valerate on the activation of cyclophosphamide in vivo. J Pharmacol Exp Ther 1972; 180: 475-83
88. Jacobs RF. Multiple drug-resistant tuberculosis. Clin Infect Dis 1994; 19: 1-10
89. Kesse D, Hall TC. Transport and phosphorylation as factors in the antitumour action of cytosine arabinoside. Science 1967; 56: 240-1
90. Cornwell MM, Gottesman MM, Pastan I. Increase vinblastine binding to membrane vesicles from multidrug-resistant KB cells. J Biol Chem 1986; 261: 7921-8
91. Cornwell JA, Safa AR, Felsted WI, et al. Membrane vesicles from multi-drug-resistant human cancer cells contain a specific 150-170 KDa protein detected by photo affinity. Proc Natl Acad Sci USA 1986; 83: 3847-50
92. Kaye SB. The multidrug resistance phenotype. Br J Cancer 1988; 58: 691-4
93. Coleman K, Athalye M, Clancey A, et al. Bacterial resistance mechanisms as therapeutic targets. J Antimicrob Chemother 1994; 33: 1091-116
94. Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 1994; 264: 382-8
95. Poole K. Bacterial multidrug resistance: emphasis on efflux mechanisms and Pseudomonas aeruginosa. J Antimicrob Chemother 1994; 34: 453-6
96. Bell DR, Gerlach JH, Karther N, et al. Detection of P-glycoprotein in ovarian cancer: molecular marker associated with multidrug resistance. J Clin Oncol 1985; 3: 311-5
97. Dalton WS, Grogan TM, Meltzer PS, et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of a P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989; 7: 415-24
98. Goldstein LJ, Galsk JH, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 11-124
99. Kuwazuru Y, Yoshimura A, Hanada S, et al. Expression of the multiple drug transporter, P-glycoprotein, in adult leukemia cells and correlation to clinical drug resistance. Cancer 1990; 66: 868-73
100. Gerlach JH, Bell DR, Karakousis C, et al. P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol 1987; 5: 1452-60
101. Chan HSL, Bradley G, Thorner P, et al. A sensitive method for immunochemical detection of P-glycoprotein in multidrug resistant human ovarian carcinoma cell lines. Lab Invest 1988; 59: 870-5
102. Garman D, Center MS. Alterations in cell surface membranes in Chinese hamster lung cells resistant to adriamycin. Biochem Biophys Res Commun 1982; 105: 157-63
103. Richert N, Akiyama S, Shen DW, et al. Multiple drug-resistant human KB carcinoma cells have decreased amount of a 75 kDa and a 72 kDa glycoprotein. Proc Nat Acad Sci USA 1985; 82: 2230-3
104. Hromas RA, Andrews PA, Murphy MP, et al. Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Lett 1987; 34: 9-13
105. Hamilton TC, Lai GM, Rothenberg ML, et al. Mechanisms of resistance to alkylating agents and cis-platinum. In: Ozols RF, editor. Cancer treatment and research: drug resistance. Boston: Martinus Nijhoff, 1989: 151-69
106. Tsuruo T, Iida H, Tsukagoshi S, et al. Overcoming of vincristine resistance in P-388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967-72
107. Yusa K, Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites, and transport of verapamil outward across the plasma membrane of K-526/ADM cells. Cancer Res 1989; 49: 5002-6
108. Safa AR, Glover CJ, Sewell JL, et al. Identification of the multidrug-resistance related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 1987; 262: 7884-8
109. Rogan AM, Hamilton TC, Young IC, et al. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 1984; 224: 994-6
110. Thomson KS, Sanders WE, Sanders CC. USA resistance patterns among UTI pathogens. J Antimicrob Chemother 1994; 33: S9-15
111. Livermore DM. Evolution of beta-lactamase inhibitors. Intensive Care Med 1994; 20: 10-3
112. Nelsen MR, Dunner DL. Clinical and differential diagnostic aspects of treatment-resistant depression. J Psychiatr Res 1995; 29; 43-50
113. Schatzberg AF, Cole JO, Cohen BM, et al. Survey of depressed patients who have failed to respond to treatment. In: Davis JM, Mans J, editors. The affective disorders. Washington DC: Academic Psychiatric Press, 1983: 73-85
114. Keller MB, Zucker ME. Cross-over studies of chronic resistant depression. Proceedings of the VIII ECNP Congress; 1995 Sept 30-Oct 4: Venice. European Neuropharmacology 1995; 5: 198-9
115. Quitkin FM. The importance of dosage in prescribing antidepressants. Br J Psychiatry 1985; 147: 593-7
116. Meltzer HY, Hippius H. The assessment and the management of treatment resistant schizophrenia in perspective. Eur Psychiatry 1995; 1 Suppl. 10: 3s-5s
117. Gillin JC, Byerey WF. The diagnosis and management of insomnia. N Engl J Med 1990; 322: 239-48
118. Gillin JC. The long and the short of sleeping pills. N Engl J Med 1991; 324: 1735-6
119. Reynolds CF, Boysse DJ, Kupfer DJ. Developmental and biopsychosocial perspectives on the diagnosis and treatment of persistent insomnia. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 1617-29
120. Morselli PL, Guillet P. Drug development in the elderly: problems and constraints. In: Burley D, Haward CH, Mullinger B, editors. The focus for pharmaceutical knowledge. London: Macmillan, 1988: 204-21
121. Lauka PV, Hoffman NB. Decreasing medication use in a nursing-home patient care unit. Am J Hosp Pharm 1992; 49: 96-9
122. Koecheler-Schneider J, Mion LC, Frengley JD. Adverse drug reactions in an elderly out-patient population. Am J Hosp Pharm 1992; 49: 90-6
123. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinical visits. Arch Intern Med 1990; 150: 1509-10
124. Haynes RB. Introduction. In: Haynes RB, Taylor DW, Sakett DL, editors. Compliance in health care. Baltimore, London: John Hopkins University Press, 1979: 1-7
125. Darnell JC, Murray MD, Marz BL, et al. Medication use by ambulatory elderly: an in home survey. J Am Geriatr Soc 1986; 49: 1-4
126. Spagnoli A, Ostino G, Borga AD, et al. Drug-compliance and unreported drugs in the elderly. J Am Geriatr Soc 1989; 37: 619-24
127. American Association for the Retired Person. A survey on the need for a prescription drug benefit under the Medicare Program. Washington (DC): AARP, 1992 Jun
128. Vinson JM, Rich MW, Sperry JC, et al. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc 1990; 38: 1290-5
129. Leppick IE. How to get patients with epilepsy to take their medication: the problem of noncompliance. Postgrad Med 1990; 88: 253-6
130. Bloom BS. The medical, social and economic implications of disease. In: Van Eimeren W, Horisberg B, editors. Socio-economic evaluation of drug therapy. Berlin, New York: Springer Verlag 1988: 3-11
131. Clark LT. Improving compliance and increasing control of hypertension: needs of special hypertensive populations. Am Heart J 1991; 121: 664-9
132. Kruse WH. Compliance with treatment of hyperlipoproteinemia in medical practice and clinical trials. In: Cramer JA, Spilker B, editors. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991: 175-86
133. Squire A, Goldman ME, Kupersmith J, et al. Long-term antiarrhythmic therapy: problem of low drug levels and patient noncompliance. Am J Med 1984; 77: 1038
134. Vandel B, Vandel S. Facteurs pharmacocinétiques et résistance aux traitements antidepresseurs. Encephale 1986; 12: 217-22
135. Dinan TG. A rational approach to the non-responding depressed patient. Int Clin Psychopharmacol 1993; 8: 221-3
136. Rovelli M, Palmeri D, Vossler E, et al. Noncompliance in organ transplant recipients. Transplant Proc 1989; 21: 833-4
137. Nagasawa M, Smith MC, Barnes JH. Meta-analysis of correlates of diabetes patient's compliance with prescribed medications. Diabetes Educ 1990; 16: 192-200
138. Joglekar M, Mohanaruban K, Bayer AJ, et al. Can old people on anticoagulant be safely managed as out-patients? Postgrad Med J 1988; 14: 775-7
139. Bauman AE, Craig AR, Dunsmore J, et al. Removing barriers to effective self-management of Asthma. Patient Educ Couns 1989; 14: 217-26
140. Hemminki E, Brambilla DJ, McKinlay SM, et al. Use of estrogens among middle-aged Massachussetts women. DICP 1991; 25: 418-23
141. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273-7
142. Kruse W, Weber E. Dynamics of drug regimen compliance - its assessment by microprocessor based monitoring. Eur J Clin Pharmacol 1990; 38: 561-5
143. Rudd P, Ahmed S, Zachary V, et al. Improved compliance measures: application in an ambulatory antihypertensive drug trial. Clin Pharmacol Ther 1990; 48: 676-85
144. Krall R. Effect of patient compliance on safety. In: Cramer JA, Spilker B, editors. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991: 19-25
145. Beardon PHG. Primary non compliance with prescribed medications in primary care. BMJ 1993; 307: 846-8
146. Kruse W, Schlierf G, Weber E. Monitoring compliance in clinical trials. Lancet 1990; 335: 803-4
147. Editorial. Patient compliance in clinical trials. Lancet 1993; 337: 823-4
148. Nies A. Sources of drug information. In: Goodman Gilman A, Rail TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. 8th ed. New York: McGraw-Hill Inc., 1989: 80-1
149. Mushlin AJ, Appel FA. Diagnosing potential noncompliance: physician's ability in a behavioral dimension of medical care. Arch Intern Med 1977; 150: 318-31
150. Norrell SE. Accuracy of patient interviews and estimates by clinical staff in determining medication compliance. Soc Sci Med 1981; 15: 57-61
151. Kruse W, Schlierf G, Weber E. Continuous compliance monitoring: its utility for the interpretation of drug trials. Eur J Clin Pharmacol 1989; 36 Suppl. A: 289
152. Spilker B. Methods of assessing and improving patient compliance in clinical trials. In: Cramer JA, Spilker B. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991: 37-56
153. Cramer JA. Identifying and improving compliance patterns: a composite plan for health care providers. In: Cramer JA, Spilker B, editors. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991: 387-92
154. Efron B, Feldman D. Compliance as explanatory variable in clinical trials. J Am Stat Assoc 1991; 86: 9-26
155. Hasford J. Biometric issues in measuring and analyzing partial compliance in clinical trials. In: Cramer JA, Spilker B, editors. Patient compliance in medical practice and clinical trials. New York: Raven Press 1991; 265-81
156. Morselli PL, Cazor JL. The benefit/risk ratio during the development of a new drug. In: Boissel JP, Caulin, Teule M, editors. Recent trends in clinical pharmacology. Colloque INSERM 205. London, Paris: John Libbey 1991: 175-86
157. Morselli PL, Baruzzi A, Bossi L, et al. Intensive long-term monitoring in resistant epileptic patients: results of a two-year study. In: Wada A, Penry JK, editors. Advances in epileptology. Xth Epilepsy International Symposium. New York: Raver Press 1980; 99-107
158. Sjöqvist F. Polymorphic drug oxidation: implication for therapeutic drug monitoring. In: Alvan G, Balant LP, Bechtel PR, et al., editors. European Consensus Conference on Pharmacogenetics. EUR 12379-EN. Bruxelles, Luxembourg: Europian Commission, 1990; 97-106
159. Monaco F, Riccio A, Benna, et al. Further observations on carbamazepine plasma levels in epileptic patients. Neurology 1976; 26: 936-43
160. Milano Collaborative Group for Studies on Epilepsy. Long-term intensive monitoring in the difficult patient: preliminary results of 16 months' observations. Usefulness and limitations. In: Gardner-Thorpe C, Janz D, Meinardi H, et al., editors. Antiepileptic drug monitoring. Kent: Pitman Medical, 1977: 197-212
161. Loiseau P, Battellocchi S, Brachet-Liermain AB, et al. Evaluation of the role of plasma level monitoring and its consequences in the therapeutic management of epileptics: a longitudinal study with phenobarbitone and phenytoin in 242 patients. In: Johannessen S, Morselli PL, Pippenger CE, et al., editors. Antiepileptic therapy: advances in drug monitoring. New York: Raven Press, 1980: 271-6
162. Loo H, Benyacoub AK, Rovei V, et al. Long-term monitoring of tricyclic antidepressant plasma concentrations. Br J Psychiatry 1980; 137: 444-51